Hyundai Bio Receives MFDS Approval for Phase 1 Clinical Trial Plan of COVID-19 Treatment

[Asia Economy Reporter Oh Hyung-gil] Hyundai Bio announced on the 11th that it has received approval from the Ministry of Food and Drug Safety for the Phase 1 clinical trial plan of 'CP-COV03,' a COVID-19 treatment drug under development.

Hyundai Bio had applied to the Ministry of Food and Drug Safety in September for the Phase 1 clinical trial plan of 'CP-COV03,' an antiviral drug developed as an oral improved formulation of niclosamide.

The company stated, "Niclosamide is expected to have high antiviral efficacy against coronavirus (SARS-CoV-2), but it has low bioavailability. CP-COV03 improves the bioavailability of niclosamide, raising expectations for its potential as a COVID-19 treatment."